DBV Technologies (NASDAQ:DBVT) Share Price Crosses Above Fifty Day Moving Average – Time to Sell?

DBV Technologies S.A. (NASDAQ:DBVT)’s stock price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $20.52 and traded as high as $21.93. DBV Technologies shares last traded at $21.46, with a volume of 75,827 shares trading hands.

Analyst Ratings Changes

DBVT has been the topic of a number of research analyst reports. Citigroup restated an “outperform” rating on shares of DBV Technologies in a report on Wednesday, December 17th. Wall Street Zen raised DBV Technologies from a “sell” rating to a “hold” rating in a research note on Sunday, February 8th. HC Wainwright set a $40.00 target price on DBV Technologies in a report on Thursday, December 18th. Citizens Jmp lifted their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a report on Wednesday, December 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of DBV Technologies in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, DBV Technologies has a consensus rating of “Moderate Buy” and an average price target of $38.25.

DBV Technologies Stock Up 1.9%

The firm has a market cap of $861.75 million, a P/E ratio of -4.15 and a beta of -0.98. The business has a fifty day simple moving average of $20.52 and a 200-day simple moving average of $15.24.

Insider Buying and Selling

In related news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the sale, the insider owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 3,369,627 shares of company stock worth $15,489,908 over the last 90 days. Insiders own 1.44% of the company’s stock.

Institutional Trading of DBV Technologies

A number of hedge funds have recently made changes to their positions in the stock. Nan Fung Trinity HK Ltd. bought a new position in DBV Technologies during the 2nd quarter valued at approximately $340,000. Vivo Capital LLC purchased a new stake in shares of DBV Technologies in the second quarter worth $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies in the second quarter worth $9,649,000. Adage Capital Partners GP L.L.C. bought a new position in shares of DBV Technologies during the second quarter valued at $9,659,000. Finally, Octagon Capital Advisors LP purchased a new position in shares of DBV Technologies in the 2nd quarter worth about $9,315,000. 71.74% of the stock is owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.